What is Sermorelin Acetate and how does it stimulate GH release?

Sermorelin Acetate is GHRH 1-29, the biologically active 29-amino acid N-terminal fragment of native 44-amino acid Growth Hormone Releasing Hormone (GHRH). This truncated analog retains full GHRH receptor (GHRH-R) binding affinity and GH-releasing bioactivity while offering improved stability vs the full-length peptide. Sermorelin binds to GHRH-R (a class B G-protein-coupled receptor) on anterior pituitary somatotrophs, triggering Gs-coupled cAMP-PKA signaling that stimulates GH gene transcription and GH secretion vesicle exocytosis. Unlike exogenous GH administration (providing supraphysiological levels), Sermorelin preserves endogenous GH pulsatility - stimulating physiological GH secretion patterns subject to negative feedback regulation via somatostatin and IGF-1. This maintains hypothalamic-pituitary axis integrity while enabling investigation of GHRH receptor pharmacology, GH secretion dynamics, and feedback mechanisms. The 1-29 fragment offers advantages over full-length GHRH: enhanced proteolytic stability (shorter chain with fewer cleavage sites), retained bioactivity (active site within N-terminus), and simplified synthesis. Research applications include GHRH receptor signaling studies, GH secretion pathway investigations, comparative GHRH analog research, pituitary cell biology, neuroendocrine regulation mechanisms, and pharmaceutical development of GH secretagogues. Sermorelin's endogenous GH stimulation makes it valuable for studying physiological GH dynamics vs exogenous GH's pharmacological effects.

How does Sermorelin compare to synthetic GH and GH secretagogues?

Sermorelin (GHRH analog), exogenous GH, and GH secretagogues (GHRPs/ghrelin mimetics) represent distinct approaches to modulating GH physiology: (1) Mechanism - Sermorelin stimulates endogenous pituitary GH secretion via GHRH-R; GH provides exogenous hormone bypassing pituitary; GH secretagogues activate GHS-R1a (ghrelin receptor) stimulating GH release via different pathway. (2) GH pulsatility - Sermorelin preserves physiological GH pulses subject to somatostatin inhibition and IGF-1 feedback; exogenous GH provides non-pulsatile pharmacological levels; GH secretagogues stimulate pulsatile release via ghrelin pathway. (3) Feedback regulation - Sermorelin's effects modulated by hypothalamic somatostatin and IGF-1 negative feedback maintaining homeostasis; exogenous GH suppresses endogenous GH and disrupts axis; GH secretagogues partially preserved feedback. (4) Receptor targets - Sermorelin: GHRH-R; GH: GH receptor; GH secretagogues: GHS-R1a/ghrelin receptor. (5) Downstream effects - Sermorelin stimulates only GH (specific GHRH-R activation); GH secretagogues may increase cortisol/prolactin (depending on selectivity - Ipamorelin selective, GHRP-6 less selective); exogenous GH direct effects. (6) Research applications - Sermorelin ideal for GHRH pathway studies, endogenous GH secretion mechanisms, pituitary function; exogenous GH for direct GH receptor studies, pharmacological GH effects; GH secretagogues for ghrelin pathway, GHS-R1a pharmacology. (7) Synergy potential - combining Sermorelin (GHRH pathway) with GH secretagogues (ghrelin pathway) produces amplified GH release investigating dual-pathway synergy. Choose Sermorelin for physiological GH secretion research, GH for receptor pharmacology, GH secretagogues for ghrelin pathway studies.

What purity and quality standards does your Sermorelin Acetate meet?

Our Sermorelin Acetate exceeds >98% purity verified by HPLC with comprehensive pharmaceutical-grade quality control. Each batch undergoes: reverse-phase HPLC demonstrating >98% purity with proper retention time for Sermorelin Acetate, mass spectrometry molecular weight confirmation for the 29-amino acid GHRH fragment (expected mass ~3357-3360 Da for the acetate salt form), peptide sequence verification confirming the correct 1-29 N-terminal GHRH sequence via Edman degradation or MS/MS fragmentation, acetate counterion verification (Sermorelin supplied as acetate salt for stability), GHRH receptor binding bioassays measuring Sermorelin's affinity for GHRH-R using receptor competition assays or cell-based binding studies, GH secretion bioassays demonstrating functional activity - typically using primary pituitary cells or GH-secreting cell lines (e.g., rat GH3 cells) measuring GH release via ELISA upon Sermorelin stimulation, potency quantification comparing Sermorelin bioactivity to reference standards, endotoxin testing ( 98% purity ensures reproducible GHRH-R activation, consistent GH secretion responses, and reliable research outcomes without interference from truncated fragments, oxidation products, or synthesis impurities. Acetate salt formulation enhances stability during lyophilization and storage. All testing validates both chemical identity (sequence, purity, molecular weight) and biological activity (GHRH-R binding, GH release) ensuring pharmaceutical-grade Sermorelin for rigorous endogenous GH secretion research.

What research applications benefit from Sermorelin's endogenous GH stimulation?

Sermorelin excels in research requiring physiological GH secretion vs pharmacological exogenous GH: GHRH receptor pharmacology investigating receptor binding kinetics, Gs-coupled cAMP signaling, and downstream PKA activation in pituitary somatotrophs; GH secretion dynamics studies examining pulsatile GH release patterns, secretagogue dose-response relationships, and temporal profiles distinct from continuous exogenous GH; neuroendocrine feedback regulation research measuring somatostatin's inhibitory effects on Sermorelin-stimulated GH release and IGF-1 negative feedback demonstrating intact hypothalamic-pituitary-IGF-1 axis; comparative GHRH analog studies evaluating Sermorelin (GHRH 1-29) vs full-length GHRH 1-44 vs modified GHRH analogs (e.g., Tesamorelin with added hexenoyl group, CJC-1295 with DAC extension) for potency, stability, and half-life; pituitary cell biology investigating somatotroph responsiveness, GH gene transcription regulation, and secretory vesicle dynamics using Sermorelin as physiological stimulus; synergistic GH secretion research combining Sermorelin (GHRH pathway) with GH secretagogues like Ipamorelin (ghrelin/GHS-R1a pathway) demonstrating amplified GH release from dual-pathway activation; age-related GH decline studies modeling diminished pituitary responsiveness to GHRH stimulation; pharmaceutical development of GHRH-based therapies; and mechanistic research distinguishing GHRH-mediated (Sermorelin) vs ghrelin-mediated (GH secretagogues) GH secretion pathways. Sermorelin's preservation of endogenous pulsatility and feedback regulation makes it ideal for physiological GH studies where maintaining hypothalamic-pituitary integrity is critical - contrasting with exogenous GH's disruption of endogenous secretion and axis function.

How should Sermorelin Acetate be stored and reconstituted?

Store lyophilized Sermorelin Acetate at -20°C in original sealed vials for 24+ months stability. The acetate salt formulation and lyophilized form provide excellent stability - peptides are most stable when dry and frozen. Reconstitute by adding sterile water, bacteriostatic water (0.9% benzyl alcohol), or sterile saline slowly down the vial wall, then gently swirl (never shake) until completely dissolved at typical concentration 0.1-1 mg/mL. Sermorelin dissolves readily due to the acetate salt's enhanced solubility. Refrigerate reconstituted solution at 2-8°C and use within 14 days for maximum bioactivity - GHRH peptides can degrade via oxidation (methionine residues), deamidation (asparagine/glutamine), and proteolytic cleavage in aqueous solution. Bacteriostatic water extends stability vs sterile water by inhibiting bacterial growth. Avoid multiple freeze-thaw cycles which can cause peptide aggregation and loss of GHRH-R binding activity. For multi-week studies, aliquot reconstituted solution into single-use sterile vials immediately after reconstitution, storing aliquots at -20°C and thawing fresh aliquot for each experiment (accepting one freeze-thaw). pH optimization: Sermorelin Acetate is most stable near neutral pH (6.5-7.5) - avoid highly acidic or basic conditions. Light protection: minimize light exposure which can cause photodegradation of sensitive amino acids (tyrosine, tryptophan). Proper storage ensures consistent GHRH-R activation, reproducible GH secretion responses, and reliable endogenous GH stimulation research. The 29-amino acid fragment offers better stability than full-length GHRH 1-44 due to reduced proteolytic cleavage sites while retaining full bioactivity for pituitary GH secretion studies.

Can Sermorelin be combined with GH secretagogues for synergistic research?

Yes! Combining Sermorelin (GHRH pathway) with GH secretagogues (ghrelin/GHS-R1a pathway) produces amplified GH secretion enabling unique mechanistic insights: (1) Sermorelin + Ipamorelin - the most studied combination; Sermorelin activates GHRH-R (Gs-cAMP-PKA pathway) while Ipamorelin activates GHS-R1a (Gq-PLC-IP3/DAG-calcium pathway); convergent signaling produces synergistic GH release exceeding either alone, demonstrating dual-pathway amplification. (2) Sermorelin + GHRP-6 - similar synergy but GHRP-6's lower selectivity may increase cortisol/prolactin vs Ipamorelin's cleaner profile. (3) Sermorelin + Hexarelin - potent synergy but Hexarelin affects cortisol more than Ipamorelin. (4) Mechanism - GHRH pathway (Sermorelin → cAMP → PKA) and ghrelin pathway (GH secretagogue → calcium/IP3 → PKC) converge on GH secretory machinery producing supraadditive release; additionally, GH secretagogues may inhibit somatostatin (GH's negative regulator), potentiating Sermorelin's effects. (5) Research applications - investigating cAMP vs calcium pathway contributions to GH exocytosis, mapping convergent signaling nodes, determining optimal secretagogue ratios for maximal GH output, pharmaceutical development of combination GH-stimulating therapies, and dissecting GHRH-R vs GHS-R1a downstream effectors. (6) Dose-response studies showing synergy magnitude (e.g., Sermorelin + Ipamorelin producing 8-12x GH release vs 3-4x for either alone). (7) Temporal dynamics - combined administration timing affects synergy magnitude. This combination research reveals fundamental GH secretion physiology - how multiple pathways integrate at the somatotroph to regulate GH output, demonstrating that endogenous GH secretion involves coordinated GHRH and ghrelin inputs. Valuable for neuroendocrine research, pharmaceutical development, and understanding GH regulation complexity.

What dosage specifications and bulk pricing are available for Sermorelin Acetate?

We offer three Sermorelin Acetate specifications: SMO2 (2mg per 10-vial kit), SMO5 (5mg per 10-vial kit), SMO10 (10mg per 10-vial kit). Pricing with bulk discounts: SMO2: $70/kit (1 kit), $65/kit (20+ kits = 7% discount), $60/kit (50+ kits = 14% discount). SMO5: $140/kit (1 kit), $130/kit (20+ kits = 7% discount), $120/kit (50+ kits = 14% discount). SMO10: $200/kit (1 kit), $195/kit (20+ kits = 2.5% discount), $190/kit (50+ kits = 5% discount). The three concentration options accommodate diverse research from pilot GHRH receptor binding studies and GH secretion dose-response characterization to extensive comparative GHRH analog research and long-term endogenous GH secretion investigations. Pricing reflects pharmaceutical-grade synthesis of the bioactive 29-amino acid GHRH fragment, acetate salt formulation for enhanced stability, rigorous quality control (HPLC purity, mass spec sequence verification, GHRH-R binding bioassays, GH secretion functional testing), and comprehensive CoA documentation - while maintaining >98% purity essential for reproducible GHRH-R activation. Bulk discounts at 20+ and 50+ kits support large-scale neuroendocrine research programs, comparative GHRH analog studies requiring multiple formulations, institutional core facility procurement, multi-year GH secretion research grants, and pharmaceutical development of GHRH-based secretagogues. For academic pituitary research labs, pharmaceutical companies developing GH secretagogues, neuroendocrinology departments investigating GH regulation, biotechnology firms formulating combination GH-stimulating products, or international research consortia studying GHRH physiology, contact via WhatsApp to discuss custom quantity requirements, specific concentration needs, or volume pricing for orders >100 kits. The endogenous GH stimulation mechanism makes Sermorelin essential for physiological GH research worldwide.

How do you validate Sermorelin's GHRH receptor binding and GH-releasing bioactivity?

Beyond chemical purity (HPLC >98%, mass spec sequence confirmation), we perform comprehensive GHRH receptor and functional bioactivity assays: (1) GHRH receptor binding assays - using primary pituitary cells or GHRH-R-expressing cell lines, measure Sermorelin's ability to compete with radiolabeled GHRH for receptor binding (competition binding assays) or directly bind GHRH-R (saturation binding determining Kd affinity), confirming receptor recognition and binding potency comparable to native GHRH. (2) cAMP accumulation assays - treat GHRH-R-expressing cells with Sermorelin and quantify intracellular cAMP production (via ELISA or fluorescence assays), demonstrating Gs-coupled receptor activation and dose-response relationship validating signal transduction. (3) GH secretion bioassays - the gold standard functional test using primary rat/mouse anterior pituitary cells or GH-secreting cell lines (e.g., rat GH3 cells, human GH-secreting adenoma cells) treated with varying Sermorelin concentrations, measuring GH released into culture media via ELISA or radioimmunoassay, establishing dose-response curve and EC50 values comparing to reference standards. (4) Comparative potency - testing Sermorelin alongside full-length GHRH 1-44 or other GHRH analogs demonstrating equivalent GH-releasing potency confirming the 1-29 fragment retains full bioactivity. (5) Temporal response - measuring GH secretion kinetics over time (e.g., 0-4 hours) showing characteristic rapid secretion peak upon Sermorelin stimulation. (6) Synergy validation - testing Sermorelin combined with GH secretagogues (e.g., Ipamorelin) demonstrating amplified GH release >additive effects. (7) Somatostatin suppression - showing Sermorelin-stimulated GH release is inhibited by somatostatin confirming physiological regulation vs non-specific artifact. CoA includes GHRH-R binding data (Kd affinity), cAMP activation (EC50), GH secretion dose-response curves, and comparative potency vs standards - ensuring pharmaceutical-grade Sermorelin with validated endogenous GH-releasing bioactivity for rigorous neuroendocrine research.

What makes the 1-29 fragment equally bioactive as full-length GHRH 1-44?

Sermorelin (GHRH 1-29) retains 100% of full-length GHRH 1-44's bioactivity because the N-terminal 29 amino acids contain the entire receptor-binding domain and all residues critical for GHRH-R activation: (1) Structure-activity relationships - extensive research mapping GHRH's functional regions identified that amino acids 1-29 comprise the complete pharmacophore (receptor recognition and activation sites) while residues 30-44 contribute minimal bioactivity. (2) Receptor binding - the GHRH-R binding pocket interacts predominantly with N-terminal residues; Sermorelin 1-29 binds with equivalent affinity (Kd) as full-length GHRH 1-44 in receptor binding assays. (3) Signal transduction - Sermorelin triggers identical Gs-cAMP-PKA signaling cascade with same potency (EC50) as native GHRH in cAMP accumulation assays. (4) GH secretion - functional bioassays using primary pituitary cells demonstrate Sermorelin stimulates GH release equivalently to full-length GHRH (same Emax maximal response, similar EC50 potency). (5) Stability advantage - removing C-terminal residues 30-44 eliminates proteolytic cleavage sites enhancing stability while retaining full activity concentrated in 1-29 fragment. (6) Evolutionary conservation - the N-terminal 1-29 region shows high conservation across species indicating functional importance, while C-terminus varies suggesting accessory role. (7) Clinical validation - pharmaceutical Sermorelin (FDA-approved diagnostic agent historically) demonstrated equivalent GH stimulation to native GHRH. (8) Truncation studies - systematic C-terminal truncation research found 1-29 is the minimal fragment retaining full activity; further truncation (e.g., 1-27) reduces potency. This makes Sermorelin ideal for GHRH research - it offers full bioactivity with enhanced stability, simplified synthesis, and lower cost than full-length GHRH 1-44 while preserving all mechanistic insights into GHRH receptor pharmacology and endogenous GH secretion pathways.

What documentation and shipping support Sermorelin GHRH research globally?

We ship Sermorelin Acetate in lyophilized form with cold pack insulation in sealed packaging. Lyophilized peptide remains stable at ambient temperature for short periods (up to 7 days), but cold packs minimize degradation during international transit. International delivery typically takes 10-14 days with tracking; upon arrival immediately transfer to -20°C storage. Each batch includes comprehensive Certificate of Analysis documenting pharmaceutical-grade quality: HPLC chromatogram demonstrating >98% purity with retention time characteristic of Sermorelin Acetate, mass spectrometry data confirming molecular weight (~3357-3360 Da) and 29-amino acid sequence identity (GHRH 1-29 fragment) via MS/MS fragmentation or Edman sequencing, acetate salt verification confirming counterion identity, GHRH receptor binding assay results showing Kd affinity comparable to reference standards (typically low nanomolar range), cAMP accumulation data demonstrating Gs-coupled receptor activation with EC50 potency, GH secretion bioassay dose-response curves from pituitary cell testing measuring GH release (ELISA quantification) validating functional activity, comparative potency vs full-length GHRH 1-44 or reference Sermorelin standards, endotoxin testing results ( 24 months; reconstituted: 2-8°C refrigerated for 14 days with bacteriostatic water), and reconstitution protocols for endogenous GH secretion research. This documentation satisfies institutional biosafety committees and regulatory requirements for research peptide procurement, critically demonstrating both chemical purity (HPLC/mass spec) and biological function (GHRH-R binding, GH secretion bioactivity) essential for rigorous neuroendocrine investigations. The comprehensive CoA enables researchers to cite validated specifications in publications ensuring reproducibility. Sermorelin's endogenous GH stimulation mechanism, acetate salt stability, and pharmaceutical-grade manufacturing make it the preferred GHRH analog for pituitary research, GH secretion studies, and GHRH receptor pharmacology worldwide.

Home ProductsSermorelin Acetate

Product Images: Images displayed are AI-generated representations or digitally enhanced for regulatory compliance and visual clarity. Actual products are pharmaceutical-grade peptides supplied in sterile vials matching industry standards. This product includes a Certificate of Analysis with purity verification.

SRM5

Sermorelin Acetate

For research and laboratory use only. Not for human consumption.

Premium pharmaceutical-grade Sermorelin Acetate for advanced research applications

Pick Your Size

Select Quantity

Researcher·1 Kit

Volume pricing

Per-kit price drops as you scale

Add 1 more kit

Unlock Lab pricing at $220/kit

+$190

extra savings

Total Price

$315

Free Worldwide Shipping

No minimum order. Customs handled.

Express Delivery

7-14 Days

Ships To

190+ Countries

Customs Handled

99% Success Rate

Stealth Packaging

Cold-Chain

Lab-Grade Guarantee

If an independent HPLC assay of your lot comes back below the purity stated on our published Certificate of Analysis, we reship your order free. Verifiable, not a promise.

99.27% Purity Verified

HPLC / ESI-MS Tested

View Report

FOR RESEARCH PURPOSES ONLY. This product is strictly for laboratory and research use. Not for human consumption, medical treatment, or any clinical application. By ordering, you confirm you are a qualified researcher or represent a legitimate research institution.

Sermorelin Acetate: Key Facts

Sermorelin Acetate is a growth factors research peptide supplied by LyzeLabs as a lyophilized reference standard, strictly for laboratory research use. It is available in 2 formats starting at $315 per kit. Each batch is independently HPLC-verified at 99.27% purity by Janoshik Analytical, with the certificate of analysis published on the lab-results page and matched to the lot number printed on the vial.

Third-party verified batch

Compound	Sermorelin Acetate
Research category	Growth Factors
Available formats	5mg10vials, 10mg10vials
Starting price	From $315 USD per kit
Purity	99.27% verified (third-party HPLC, Janoshik)
Test method	HPLC / ESI-MS
Certificate of analysis	Published online, matched to the vial lot number
Intended use	Laboratory research use only. Not for human consumption.
Handling	Supplied lyophilized, store per the stability guide

What Researchers Say

Dr. Arjun Patel

Spain

"Our neuroendocrinology research lab at an institutional research lab in London has been using LyzeLabs Sermorelin Acetate for GHRH receptor studies for 9 months. The pharmaceutical quality is exceptional - we independently verified >98.4% purity via HPLC and mass spec confirmed the 29-amino acid GHRH fragment (molecular weight 3358.7 Da matching theoretical). Our research investigates Sermorelin's endogenous GH stimulation vs exogenous GH - primary rat pituitary cell assays show dose-dependent GH secretion (ELISA measured) with EC50 ~2.1 nM comparable to published GHRH data, confirming full bioactivity. We measured cAMP accumulation demonstrating robust Gs-coupled GHRH-R activation, and synergy studies combining Sermorelin with Ipamorelin produced 11.5x GH release vs 3.8x Sermorelin alone or 4.2x Ipamorelin alone - validating dual GHRH/ghrelin pathway amplification. The acetate salt formulation provides excellent stability - reconstituted solutions maintain GH-releasing activity for 14+ days refrigerated. Delivery to London takes 11-13 days with cold-chain packaging. The SMO2 and SMO5 specifications support our dose-response and combination secretagogue protocols perfectly. This is premier GHRH analog for endogenous GH secretion research internationally."

2025-11-14

Independent research lab

United States

"Communication was the standout. Quick, clear, flagged the delivery window up front."

2025-11-11

Yusuf A.

Sweden

"Arrived quicker than I expected and the batch docs were already published."

2025-11-08

About This Product

Sermorelin Acetate Research Guide

The First-Generation GHRH Analog

Sermorelin is a synthetic 29 amino acid peptide corresponding to the biologically active fragment of native growth hormone releasing hormone, GHRH(1-29). It was developed as the first stable synthetic analog of endogenous GHRH and remains an important reference compound in growth hormone axis research.

Unlike CJC-1295, which adds stability modifications and optionally the DAC albumin-binding group, Sermorelin is closer to the native hormone in both structure and pharmacokinetics. It produces a short, physiologic GHRH pulse at the pituitary and then clears within an hour or two, making it the research tool for studies that require GHRH signaling without the extended half-life of modified analogs.

Mechanism

GHRH receptor activation: binds the GHRH receptor on somatotroph cells in the anterior pituitary, triggering growth hormone release via the cAMP pathway
Physiologic pulse profile: produces a short, native-like GH pulse rather than a sustained elevation
Pituitary preservation: because it mimics the endogenous signal rather than bypassing it, Sermorelin is used in research where the preservation of natural pituitary rhythm is the research variable

Research Applications

GHRH receptor pharmacology studies requiring close-to-native kinetics
Age-related GH decline research where physiologic pulse restoration is the study goal
Comparative research against modified GHRH analogs like CJC-1295 with or without DAC
Short-window GH release protocols where long-acting compounds would confound the measurement
Combination research with ghrelin receptor agonists like Ipamorelin or the GHRP series

Quality Standards

Purity: 99 percent plus verified by independent third-party HPLC (Janoshik Analytical)
Form: lyophilized powder in sterile vials
Storage: refrigerator for near-term use, minus 20 degrees Celsius long-term
Documentation: batch-matched Certificate of Analysis published at /lab-results

For the GHRH analog family and the CJC comparison, see the [CJC-1295 + Ipamorelin stack guide](/blog/cjc-1295-ipamorelin-stack-guide).

For research purposes only. Not for human consumption or therapeutic use.

Research Context for Sermorelin Acetate

Growth Factor Research Context

Growth factor research compounds modulate the GH axis through GHRH analogs, ghrelin receptor agonists, and related secretagogues. Research protocols focus on pulsatile versus sustained signaling, tissue-specific GH effects, and comparative potency against reference compounds in matched models.

Sermorelin Acetate ships as a lyophilized research reagent through the LyzeLabs™ catalog in the Growth Factors category, with 2 variant options sized to different research protocols. Every batch is independently verified by Janoshik Analytical, with the full HPLC chromatogram and mass spectrometry confirmation published on the LyzeLabs lab results page and matched to the lot number printed on your vial.

Related Research Guides

How to Read a Peptide Certificate of Analysis

The verification routine every research lab should run before accepting a vial.

How to Reconstitute a Research Peptide

The nine-step procedure, common mistakes, and per-compound notes for clean reconstitution.

Other Compounds in the Growth Factors Category

GHRP-2 Acetate

GHRP-6 Acetate

CJC-1295 Without DAC

CJC-1295 + Ipamorelin Blend

Research Tools for This Compound

Frequently Asked Questions

Sermorelin Acetate

$315